logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Alkermes, Inc.


USPTO Granted Patents = 76

% Expired Patents = 13.2



Trademarks = 16

Forward Citations = 2,954

Loading Chart...
Loading Chart...

95 inventors (with patents filed for the assignee):

goldMedal Juan C Alvarez (11 out of 15 patents)

silverMedal Steven G Wright (10 out of 43 patents)

bronzeMedal Lewis D Pennington (8 out of 22 patents)

4.  J Michael Ramstack (8 out of 44 patents)

5.  Joyce M Hotz (8 out of 30 patents)

6.  Phillip M Friden (8 out of 13 patents)

7.  Nathan Oliver Fuller (7 out of 11 patents)

8.  Michael E Rickey (7 out of 31 patents)

9.  John Adams Lowe, Iii (7 out of 83 patents)

10.  Brian M Aquila (6 out of 28 patents)

11.  Hoan Huynh (6 out of 11 patents)

12.  Shawn L Lyons (6 out of 28 patents)

13.  Rajesh Kumar (6 out of 14 patents)

14.  Brian Kenneth Raymer (6 out of 15 patents)

15.  Younggi Choi (6 out of 6 patents)


Core Competencies:
Opioid Compounds
Histone Deacetylase Inhibitors
Microencapsulation
Sustained Release
Polymorphic Forms
Fc Fusion Proteins
IL-10 Modulation
Cationized Antibodies
Transferrin Receptor
Pain Treatment
Inhalable Formulations
Mucin-Domain Polypeptides

76 patents:

1. 12637476 - Substituted carbamate macrocyclic compounds and related methods of treatment (2026-05-26),
2. 12441710 - Substituted piperidino compounds and related methods of treatment (2025-10-14),
3. 12054495 - Substituted macrocyclic compounds and related methods of treatment (2024-08-06),
4. 12006330 - Substituted macrocyclic compounds and related methods of treatment (2024-06-11),
5. 11987580 - Bicyclic inhibitors of histone deacetylase (2024-05-21),
6. 11912702 - Substituted pyridines as inhibitors of histone deacetylase (2024-02-27),
7. 11858939 - Hetero-halo inhibitors of histone deacetylase (2024-01-02),
8. 11760747 - Substituted piperidino compounds and related methods of treatment (2023-09-19),
9. 11542276 - Substituted macrocyclic compounds and related methods of treatment (2023-01-03),
10. 11534480 - Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties (2022-12-27),
11. 11286256 - Bicyclic inhibitors of histone deacetylase (2022-03-29),
12. 11225479 - Bicyclic inhibitors of histone deacetylase (2022-01-18),
13. 11225475 - Substituted pyridines as inhibitors of histone deacetylase (2022-01-18),
14. 11180455 - Compounds for the treatment of pain (2021-11-23),
15. 10919902 - Hetero-halo inhibitors of histone deacetylase (2021-02-16),
Alkermes, Inc. is a biopharmaceutical company based in Cambridge, MA, specializing in the development of innovative therapies for central nervous system disorders and addiction. The company focuses on opioid compounds and employs advanced technologies such as histone deacetylase inhibitors, microencapsulation, and sustained release formulations. Alkermes is also engaged in research related to Fc fusion proteins and IL-10 modulation, aiming to address complex medical needs through its diverse portfolio of therapeutic solutions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Alkermes, Inc.
76 Patents

#35 in Cambridge, MA

#267 in Massachusetts

#4,837 in US

#9,873 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Alkermes, Inc.

Forward Citations = 2,954

95 inventors:

goldMedal Juan C Alvarez (11 out of 15 patents)

silverMedal Steven G Wright (10 out of 43 patents)

bronzeMedal Lewis D Pennington (8 out of 22 patents)

4.  J Michael Ramstack (8 out of 44 patents)

5.  Joyce M Hotz (8 out of 30 patents)

Please report any incorrect information to [email protected]
Loading…